ArticleMicrobial cell factories2025
Identification of novel Gramicidin S analogs from Aneurinibacillus aneurinilyticus isolated from corn steep liquor with potential antifungal activity.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In the existing literature, there is ample information available concerning the analogs constituting linear Gramicidin (Gramicidin A). However, the literature lacks information regarding the microbial production of cyclic Gramicidin S (GR-S) and the study of its analogs' amino acid composition. Thus, in this study, GR-S was produced by Aneurinibacillus aneurinilyticus, isolated from corn steep liquor (CSL) and grown in synthetic or CSL-based medium. The extract was obtained from microbial biomass and underwent analysis with ultra performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) to ascertain the presence and abundance of GR-S clusters, identifying five GR S analogs. Hence, when using a synthetic medium, the dominant cluster compromised the sequence Val-Orn-Leu-Phe-Pro-Val-Orn-Leu-Phe-Pro. Contrarily, when using CSL-based medium, the main analog was composed of Val-Orn-Leu-Phe-Pro-Val-Lys-Leu-Phe-Pro. In the remaining analogs, one or both Ornithine (Orn) residues were replaced by Lysine (Lys) or diaminobutyric acid (D-Dab). Microscopy images revealed that the use of CSL-based medium resulted in a lower yield of GR-S and a higher accumulation of vacuoles compatible with the presence of intracellular polyhydroxyalkanoates (PHA) when comparing with TSB medium. The antifungal assay revealed a superior conidial inhibition activity of GR-S extract under evaluation against Aspergillus brasiliensis in comparison to the commercial GR-S. Consequently, it can be concluded that this novel microbial GR-S extract exhibits favorable antifungal activity, positioning it as a promising candidate for antimicrobial treatments. However, further research is necessary to address the global challenge of antibiotic-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.